TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Brief Summary: This is a multicenter, double- blind extension study of Oral Budesonide Suspension (OBS) in adults and adolescents (11 to 55 years of age, inclusive) with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-301 induction study (NCT02605837). The primary objective is to evaluate the maintenance of efficacy of OBS over 36 weeks. Maintenance of efficacy will be measured by the peak eosinophilic count and Dysphagia Symptom Questionnaire (DSQ) score.


Options:
A: Arm Label: Oral Budesonide Suspension (OBS); Type: EXPERIMENTAL; Interventions: Drug: Oral Budesonide Suspension (OBS) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral Budesonide Suspension (OBS); Assigned to Arm(s): Oral Budesonide Suspension (OBS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arms A OBS Completers/ Responders; Type: EXPERIMENTAL; Interventions: Drug: Oral Budesonide Suspension (OBS) | Arm Label: Arm B OBS Completers/ Responders; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Arm C OBS Completers/ Non-Responders; Type: EXPERIMENTAL; Interventions: Drug: Oral Budesonide Suspension (OBS) | Arm Label: Arm D Placebo Completers; Type: EXPERIMENTAL; Interventions: Drug: Oral Budesonide Suspension (OBS) | Intervention Type: DRUG; Name: Oral Budesonide Suspension (OBS); Assigned to Arm(s): Arm C OBS Completers/ Non-Responders, Arm D Placebo Completers, Arms A OBS Completers/ Responders | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm B OBS Completers/ Responders
C: Arm Label: Oral Budesonide Suspension; Type: EXPERIMENTAL; Interventions: Drug: Oral Budesonide Suspension (MB-9) | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral Budesonide Suspension (MB-9); Assigned to Arm(s): Oral Budesonide Suspension | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): 2, 3, 4 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Naltrexone and Bupropion Combination on Weight Loss and Smoking Cessation in Obese, Cigarette-smoking Patients With Schizophrenia
Brief Summary: The purpose of this research is to observe the efficacy of Naltrexone and Bupropion combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.


Options:
A: Arm Label: Naltrexone and Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Bupropion | Arm Label: Placebo Naltrexone and Bupropion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Naltrexone, Drug: Placebo Bupropion | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone and Bupropion | Intervention Type: DRUG; Name: Placebo Naltrexone; Assigned to Arm(s): Placebo Naltrexone and Bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Naltrexone and Bupropion | Intervention Type: DRUG; Name: Placebo Bupropion; Assigned to Arm(s): Placebo Naltrexone and Bupropion
B: Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment
C: Arm Label: Nicotine E-Cigarette and Counseling; Type: EXPERIMENTAL; Interventions: Other: Nicotine E-Cigarette, Behavioral: Counseling | Arm Label: Non-Nicotine E-Cigarette and Counseling; Type: OTHER; Interventions: Other: Non-Nicotine E-Cigarette, Behavioral: Counseling | Arm Label: Counseling; Type: OTHER; Interventions: Behavioral: Counseling | Intervention Type: OTHER; Name: Nicotine E-Cigarette; Assigned to Arm(s): Nicotine E-Cigarette and Counseling | Intervention Type: OTHER; Name: Non-Nicotine E-Cigarette; Assigned to Arm(s): Non-Nicotine E-Cigarette and Counseling | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Counseling, Nicotine E-Cigarette and Counseling, Non-Nicotine E-Cigarette and Counseling
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Naltrexone and Bupropion Combination on Weight Loss and Smoking Cessation in Obese, Cigarette-smoking Patients With Schizophrenia
Brief Summary: The purpose of this research is to observe the efficacy of Naltrexone and Bupropion combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole or Perphenazine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Aripiprazole or Perphenazine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine; Assigned to Arm(s): 1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betahistine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Betahistine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): 2
C: Arm Label: Naltrexone and Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Bupropion | Arm Label: Placebo Naltrexone and Bupropion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Naltrexone, Drug: Placebo Bupropion | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone and Bupropion | Intervention Type: DRUG; Name: Placebo Naltrexone; Assigned to Arm(s): Placebo Naltrexone and Bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Naltrexone and Bupropion | Intervention Type: DRUG; Name: Placebo Bupropion; Assigned to Arm(s): Placebo Naltrexone and Bupropion
D: Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Intensity Weight Loss for Young Adults
Brief Summary: This is a 3-arm randomized controlled trial to test the efficacy of three novel motivational approaches to weight loss with 18-25 year olds. Participants will be 18-25 year olds with a BMI of 25-45 kg/m2, randomized to: 1) Behavioral Weight Loss (BWL), 2) BWL + Autonomous Motivation (BWL+Aut) or 3) BWL + Extrinsic Motivation (BWL+Ext). All arms will receive a 6-month behavioral weight loss intervention, followed by a 6-month no-treatment follow up period.


Options:
A: Arm Label: Paper food diary; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Paper food diary | Arm Label: Online food diary; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Online food diary | Arm Label: "My Meal Mate" (smartphone application); Type: EXPERIMENTAL; Interventions: Behavioral: "My Meal Mate" (smartphone application) | Intervention Type: BEHAVIORAL; Name: "My Meal Mate" (smartphone application); Assigned to Arm(s): "My Meal Mate" (smartphone application) | Intervention Type: BEHAVIORAL; Name: Paper food diary; Assigned to Arm(s): Paper food diary | Intervention Type: BEHAVIORAL; Name: Online food diary; Assigned to Arm(s): Online food diary
B: Arm Label: Behavioral Weight Loss (BWL); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Weight Loss (BWL) | Arm Label: BWL + Autonomous Motivation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Weight Loss (BWL), Behavioral: BWL + Autonomous Motivation | Arm Label: BWL + Extrinsic Motivation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Weight Loss (BWL), Behavioral: BWL + Extrinsic Motivation | Intervention Type: BEHAVIORAL; Name: Behavioral Weight Loss (BWL); Assigned to Arm(s): BWL + Autonomous Motivation, BWL + Extrinsic Motivation, Behavioral Weight Loss (BWL) | Intervention Type: BEHAVIORAL; Name: BWL + Autonomous Motivation; Assigned to Arm(s): BWL + Autonomous Motivation | Intervention Type: BEHAVIORAL; Name: BWL + Extrinsic Motivation; Assigned to Arm(s): BWL + Extrinsic Motivation
C: Arm Label: Smartphone App Participants (APP); Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone App Participants (APP) | Arm Label: Diabetes Prevention Program Participants (DPP); Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Prevention Program Participants (DPP) | Intervention Type: BEHAVIORAL; Name: Smartphone App Participants (APP); Assigned to Arm(s): Smartphone App Participants (APP) | Intervention Type: BEHAVIORAL; Name: Diabetes Prevention Program Participants (DPP); Assigned to Arm(s): Diabetes Prevention Program Participants (DPP)
D: Arm Label: Noom Health; Type: EXPERIMENTAL; Interventions: Behavioral: Noom Health | Arm Label: Noom Digital Health; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Noom Digital Health | Intervention Type: BEHAVIORAL; Name: Noom Health; Assigned to Arm(s): Noom Health | Intervention Type: BEHAVIORAL; Name: Noom Digital Health; Assigned to Arm(s): Noom Digital Health

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
Brief Summary: The main purpose of this study is to explore the sequential therapeutic effect of CD19-targeted and CD20-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Diffuse Large B Cell Lymphoma(DLBCL)


Options:
A: Arm Label: JCAR017 1-dose schedule; Type: EXPERIMENTAL; Interventions: Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule | Arm Label: JCAR017 2-dose schedule (no longer accruing); Type: EXPERIMENTAL; Interventions: Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule | Intervention Type: BIOLOGICAL; Name: JCAR017 (lisocabtagene maraleucel) single-dose schedule; Assigned to Arm(s): JCAR017 1-dose schedule | Intervention Type: BIOLOGICAL; Name: JCAR017 (lisocabtagene maraleucel) 2-dose schedule; Assigned to Arm(s): JCAR017 2-dose schedule (no longer accruing)
B: Arm Label: Tisagenlecleucel; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel
C: Arm Label: Single dose of CTL019; Type: EXPERIMENTAL; Interventions: Biological: CTL019 | Intervention Type: BIOLOGICAL; Name: CTL019; Assigned to Arm(s): Single dose of CTL019
D: Arm Label: Diffuse Large B Cell Lymphoma(DLBCL); Type: EXPERIMENTAL; Interventions: Biological: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells | Intervention Type: BIOLOGICAL; Name: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells; Assigned to Arm(s): Diffuse Large B Cell Lymphoma(DLBCL)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Tobacco Cessation for Improving Oral Diseases - Multicenter Prospective Trial
Brief Summary: This study is to verify the efficacy of tobacco cessation in patients with oral diseases; periodontitis, dental implant and oral mucosal diseases by a multicenter prospective trial. Tobacco cessation intervention is implemented for 12 weeks. During the tobacco cessation intervention for the subjects, attending doctors implement standard treatments for their oral diseases. Improvement of each disease is evaluated between smoking cessation intervention group and non-cessation intervention group.


Options:
A: Arm Label: Group I (varenicline and placebo); Type: EXPERIMENTAL; Interventions: Other: Placebo, Other: Tobacco Cessation Counseling, Drug: Varenicline | Arm Label: Group II (placebo, nicotine patch and lozenge); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nicotine Lozenge, Drug: Nicotine Patch, Other: Placebo, Other: Tobacco Cessation Counseling | Intervention Type: DRUG; Name: Nicotine Lozenge; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Group I (varenicline and placebo)
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablet is made of lactose | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo tablet is made of lactose; Assigned to Arm(s): control group
D: Arm Label: Tobacco cessation intervention; Type: EXPERIMENTAL; Interventions: Other: Tobacco cessation intervention | Arm Label: Non-tobacco cessation intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Tobacco cessation intervention; Assigned to Arm(s): Tobacco cessation intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development of a Nutrigenetic Test for Personalized Prescription of Body Weight Loss Diets (Obekit)
Brief Summary: This study evaluates the relationship between several genetic variants and the response to a hypocaloric diet, in order to design a genetic test which permits prescribe the more personalized diet for each individual according to her genotype. Half of the participants will assigned to a moderate high protein diet, while the other half will assigned to a high carbohydrate diet.


Options:
A: Arm Label: 20% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 20% protein-diet | Arm Label: 27% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 27% protein-diet | Arm Label: 35% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 35% protein-diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 20% protein-diet; Assigned to Arm(s): 20% protein hypocaloric diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 27% protein-diet; Assigned to Arm(s): 27% protein hypocaloric diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 35% protein-diet; Assigned to Arm(s): 35% protein hypocaloric diet
B: Arm Label: Moderately high protein diet; Type: EXPERIMENTAL; Interventions: Behavioral: Moderately high protein diet | Arm Label: Low fat diet; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Moderately high protein diet; Assigned to Arm(s): Moderately high protein diet | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): Low fat diet
C: Arm Label: energy-restricted, CHO-restricted diet; Type: EXPERIMENTAL; Interventions: Other: energy-restricted, CHO-restricted diet | Arm Label: energy-restricted, CHO-rich diet; Type: ACTIVE_COMPARATOR; Interventions: Other: energy-restricted, CHO-rich diet | Intervention Type: OTHER; Name: energy-restricted, CHO-restricted diet; Assigned to Arm(s): energy-restricted, CHO-restricted diet | Intervention Type: OTHER; Name: energy-restricted, CHO-rich diet; Assigned to Arm(s): energy-restricted, CHO-rich diet
D: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity Behavior Change for Older Veterans After Dysvascular Amputation
Brief Summary: This pilot study will use mobile-health technology to deliver an intervention designed for lasting physical activity behavior change. The study will assess the feasibility of using the Physical Activity Behavior Change(PABC) intervention for Veterans with lower limb amputation. This intervention will be delivered using wrist-worn wearable activity sensors and a home-based tablet computer to allow real-time physical activity feedback and video interface between the participants and the therapist.


Options:
A: Arm Label: Standard Training+Sit-to-stand trainer; Type: EXPERIMENTAL; Interventions: Device: Sit-to-stand trainer | Arm Label: Standard Training; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Sit-to-stand trainer; Assigned to Arm(s): Standard Training+Sit-to-stand trainer
B: Arm Label: Error-augmentation training; Type: EXPERIMENTAL; Interventions: Behavioral: Error-augmentation gait training | Arm Label: Error-correction training; Type: EXPERIMENTAL; Interventions: Behavioral: Error-correction gait training | Arm Label: Supervised waking; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised walking | Intervention Type: BEHAVIORAL; Name: Error-augmentation gait training; Assigned to Arm(s): Error-augmentation training | Intervention Type: BEHAVIORAL; Name: Error-correction gait training; Assigned to Arm(s): Error-correction training | Intervention Type: BEHAVIORAL; Name: Supervised walking; Assigned to Arm(s): Supervised waking
C: Arm Label: Early PABC Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Behavior Change (PABC) | Arm Label: Wait-List Control Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Behavior Change (PABC) | Intervention Type: BEHAVIORAL; Name: Physical Activity Behavior Change (PABC); Assigned to Arm(s): Early PABC Intervention, Wait-List Control Intervention | Intervention Type: BEHAVIORAL; Name: Physical Activity Behavior Change (PABC); Assigned to Arm(s): Early PABC Intervention, Wait-List Control Intervention
D: Arm Label: Left transtibial; Type: N/A; Interventions: Device: KinetiGait | Arm Label: Right transtibial; Type: N/A; Interventions: Device: KinetiGait | Arm Label: Left transfemoral; Type: N/A; Interventions: Device: KinetiGait | Arm Label: Right transfemoral; Type: N/A; Interventions: Device: KinetiGait | Arm Label: Provider; Type: N/A; Interventions: Device: KinetiGait | Intervention Type: DEVICE; Name: KinetiGait; Assigned to Arm(s): Left transfemoral, Left transtibial, Provider, Right transfemoral, Right transtibial

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Normal Voiding Function After Surgical Repair of Pelvic Organ Prolapse: A Randomized Trial Comparing Day of Surgery Retrograde Void Trials to Standard Postoperative Day One Retrograde Void Trials
Brief Summary: The primary aim of this study is to determine if normal bladder function (the ability to empty the bladder during spontaneous urination) after surgical repair of pelvic organ prolapse returns faster in patients who have a retrograde voiding trial the day of surgery versus patients who have a retrograde voiding trial on postoperative day one. Half of participants will have a voiding trial 4 hours after surgery, while the other half will have the voiding trial postoperative day one.


Options:
A: Arm Label: voiding trial 4 hours post-op; Type: EXPERIMENTAL; Interventions: Procedure: Retrograde voiding trial | Arm Label: voiding trial post-op day 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Retrograde voiding trial | Intervention Type: PROCEDURE; Name: Retrograde voiding trial; Assigned to Arm(s): voiding trial 4 hours post-op, voiding trial post-op day 1
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Tamsulosin | Intervention Type: DRUG; Name: Tamsulosin; Assigned to Arm(s): 2
C: Arm Label: Early removal group; Type: EXPERIMENTAL; Interventions: Procedure: Early removal group | Arm Label: Normal removal group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Normal removal group | Intervention Type: PROCEDURE; Name: Early removal group; Assigned to Arm(s): Early removal group | Intervention Type: PROCEDURE; Name: Normal removal group; Assigned to Arm(s): Normal removal group
D: Arm Label: A B C; Type: EXPERIMENTAL; Interventions: Procedure: on Foley time | Intervention Type: PROCEDURE; Name: on Foley time; Assigned to Arm(s): A B C

Answer: A